A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P.
Demetri GD, et al. Among authors: borghaei h.
Clin Cancer Res. 2009 Sep 15;15(18):5910-6. doi: 10.1158/1078-0432.CCR-09-0542. Epub 2009 Sep 1.
Clin Cancer Res. 2009.
PMID: 19723647
Free PMC article.
Clinical Trial.